BCEL
Atreca
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 447.92M; Volume: 206.94K; AvgVol 3m: 333.59K; Beta: –;
Cost estimate:
P/E: –; EPS: -2.68; EPS growth quarter/prev quarter: -6.10%;
EPS growth this year: -70.30%; EPS growth past 5 years: ;
EPS ttm: -2.73;
P/S: ; P/B: 2.70; P/Cashflow: 3.21; P/FCF: ;
Sales: –; Sales growth quarter/prev quarter: ; Sales growth past 5 years: ;
Profitability:
Gross Margin: ; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -40.60%; ROE – return on equity: -42.70%; LT Debt/Equity: 0.00; Total Debt/Equity: 0.00;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 1.40%; Insider Transactions:-27.77%;
Institutional Ownership: 67.50%; Institutional Transactions: 4.00%;
Data update: 07/10/2020.